<p>Nkarta, Inc.（纳斯达克代码：NKTX - 免费报告）- Leerink Partners 的股票研究分析师在 11 月 11 日（星期二）发布的研究报告中上调了 Nkarta 的 2025 财年收益预期。Leerink Partners 的分析师 D. Graybosch 现在预计该公司在这一年将每股盈利（$1.41），高于之前的预期（$1.48）。市场普遍预计 Nkarta 当前全年的每股收益为（$1.70）。Leerink Partners 还对 Nkarta 的 2026 财年收益预期为每股（$1.65），2027 财年收益为每股（$1.77），2028 财年收益为每股（$1.55）以及 2029 财年收益为每股（$1.15）。</p>
<p>Nkarta（纳斯达克代码：NKTX - 获取免费报告）最近在 11 月 10 日（星期一）公布了其收益结果。该公司报告季度每股收益（EPS）为（$0.29），超出分析师普遍预期的（$0.32）$0.03。</p>
<p>其他一些股票研究分析师最近也对该公司发表了评论。Weiss Ratings 在 10 月 31 日（星期五）的报告中重申了对 Nkarta 股票的 “卖出（d-）” 评级。华尔街 Zen 在 10 月 25 日（星期六）的研究报告中将 Nkarta 的评级从 “卖出” 上调至 “持有”。Needham &amp; Company LLC 在 8 月 13 日（星期三）的研究报告中重申了 “买入” 评级，并设定了 Nkarta 股票的目标价为 $10.00。最后，Stifel Nicolaus 在周二的报告中将 Nkarta 股票的目标价从 $12.00 下调至 $11.00，并对该股票设定了 “买入” 评级。四位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，Nkarta 的共识评级为 “适度买入”，平均目标价为 $13.25。</p>
<p><strong>查看我们最新的 Nkarta 股票报告</strong></p>
<h2>Nkarta 价格表现</h2>
<p>NKTX 股票在周四开盘价为 $1.96。Nkarta 的 1 年最低价为 $1.31，1 年最高价为 $3.18。该股票的市值为 $139.22 百万，市盈率为 -1.42，贝塔值为 0.86。该公司有 50 日简单移动平均线为 $2.13，200 日简单移动平均线为 $2.01。</p>
<h2>对 Nkarta 的对冲基金看法</h2>
<p>一些对冲基金最近对 NKTX 的持仓进行了调整。Nuveen LLC 在第一季度购买了 Nkarta 的新头寸，价值 $258,000。Charles Schwab Investment Management Inc. 在第一季度增加了对 Nkarta 的持股，增幅为 18.0%。Charles Schwab Investment Management Inc. 目前拥有 147,551 股该公司的股票，价值 $271,000，此前在上个季度又增持了 22,538 股。Alyeska Investment Group L.P. 在第一季度将其在 Nkarta 的持股增加了 54.7%。Alyeska Investment Group L.P. 目前拥有 2,064,956 股该公司的股票，价值 $3,800,000，此前在此期间又购买了 730,260 股。Samalin Investment Counsel LLC 在第一季度将其在 Nkarta 的持股增加了 81.4%。Samalin Investment Counsel LLC 目前拥有 153,425 股该公司的股票，价值 $282,000，此前在此期间又购买了 68,850 股。最后，Monaco Asset Management SAM 在第一季度收购了 Nkarta 的新头寸，价值约 $1,496,000。机构投资者和对冲基金持有该公司 80.54% 的股票。</p>
<h2>Nkarta 公司简介</h2>
<p>（获取免费报告）</p>
<p>Nkarta, Inc. 是一家临床阶段的生物制药公司，开发和商业化用于癌症和自身免疫性疾病治疗的自然杀伤细胞疗法。该公司的主要产品候选者是 NKX019，一种针对 CD19 抗原的嵌合抗原受体 - 自然杀伤细胞（CAR NK），目前正在进行针对复发/难治性（r/r）非霍奇金淋巴瘤的 1 期临床试验，以及用于狼疮性肾炎的治疗。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Nkarta</li>
<li>保护您的投资组合免受冠状病毒影响的 3 只股票</li>
<li>关于 Holding 的抛售结束和新高即将到来的 3 个理由</li>
<li>风险承受能力，适合所有人的一刀切并不适用</li>
<li>随着沃伦·巴菲特接近退休，伯克希尔的现金储备创下新纪录</li>
<li>现在购买 P&amp;G，在其创下新高之前</li>
<li>稀土股票：并非真正的休战</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Nkarta 吗？</h2>
<p>在考虑 Nkarta 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Nkarta 并不在名单上。</p>
<p>虽然 Nkarta 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

NKTX

<p>Leerink Partners 将 Nkarta 的 2025 财年每股收益预估从（$1.48）上调至（$1.41）。分析师的评级各不相同：四个买入，一个持有，一个卖出。Nkarta 的股票开盘价为 $1.96，市值为 1.3922 亿美元。对冲基金持有该股票的 80.54%。Nkarta 开发用于癌症和自身免疫疾病的 CAR NK 疗法，目前 NKX019 正在进行 1 期临床试验</p>

<p>Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of Nkarta in a research note issued on Tuesday, November 11th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn ($1.41) per share for the year, up from their prior estimate of ($1.48). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta's FY2026 earnings at ($1.65) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.55) EPS and FY2029 earnings at ($1.15) EPS.</p>
<div class="lb-trans"><p>Nkarta, Inc.（纳斯达克代码：NKTX - 免费报告）- Leerink Partners 的股票研究分析师在 11 月 11 日（星期二）发布的研究报告中上调了 Nkarta 的 2025 财年收益预期。Leerink Partners 的分析师 D. Graybosch 现在预计该公司在这一年将每股盈利（$1.41），高于之前的预期（$1.48）。市场普遍预计 Nkarta 当前全年的每股收益为（$1.70）。Leerink Partners 还对 Nkarta 的 2026 财年收益预期为每股（$1.65），2027 财年收益为每股（$1.77），2028 财年收益为每股（$1.55）以及 2029 财年收益为每股（$1.15）。</p>
</div><p>Nkarta (NASDAQ:NKTX - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.03.</p>
<div class="lb-trans"><p>Nkarta（纳斯达克代码：NKTX - 获取免费报告）最近在 11 月 10 日（星期一）公布了其收益结果。该公司报告季度每股收益（EPS）为（$0.29），超出分析师普遍预期的（$0.32）$0.03。</p>
</div><p>A number of other equities research analysts have also recently commented on the company. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Nkarta in a report on Friday, October 31st. Wall Street Zen upgraded Nkarta from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, October 25th. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and set a $10.00 price objective on shares of Nkarta in a research report on Wednesday, August 13th. Finally, Stifel Nicolaus reduced their target price on shares of Nkarta from $12.00 to $11.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Nkarta has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $13.25.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对该公司发表了评论。Weiss Ratings 在 10 月 31 日（星期五）的报告中重申了对 Nkarta 股票的 “卖出（d-）” 评级。华尔街 Zen 在 10 月 25 日（星期六）的研究报告中将 Nkarta 的评级从 “卖出” 上调至 “持有”。Needham &amp; Company LLC 在 8 月 13 日（星期三）的研究报告中重申了 “买入” 评级，并设定了 Nkarta 股票的目标价为 $10.00。最后，Stifel Nicolaus 在周二的报告中将 Nkarta 股票的目标价从 $12.00 下调至 $11.00，并对该股票设定了 “买入” 评级。四位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，Nkarta 的共识评级为 “适度买入”，平均目标价为 $13.25。</p>
</div><p><strong>View Our Latest Stock Report on Nkarta</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Nkarta 股票报告</strong></p>
</div><h2>Nkarta Price Performance</h2>
<div class="lb-trans"><h2>Nkarta 价格表现</h2>
</div><p>Shares of NKTX opened at $1.96 on Thursday. Nkarta has a 1-year low of $1.31 and a 1-year high of $3.18. The stock has a market cap of $139.22 million, a price-to-earnings ratio of -1.42 and a beta of 0.86. The firm has a 50 day simple moving average of $2.13 and a 200-day simple moving average of $2.01.</p>
<div class="lb-trans"><p>NKTX 股票在周四开盘价为 $1.96。Nkarta 的 1 年最低价为 $1.31，1 年最高价为 $3.18。该股票的市值为 $139.22 百万，市盈率为 -1.42，贝塔值为 0.86。该公司有 50 日简单移动平均线为 $2.13，200 日简单移动平均线为 $2.01。</p>
</div><h2>Hedge Funds Weigh In On Nkarta</h2>
<div class="lb-trans"><h2>对 Nkarta 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in NKTX. Nuveen LLC purchased a new position in shares of Nkarta in the 1st quarter worth $258,000. Charles Schwab Investment Management Inc. increased its stake in Nkarta by 18.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 147,551 shares of the company's stock worth $271,000 after acquiring an additional 22,538 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of Nkarta by 54.7% in the 1st quarter. Alyeska Investment Group L.P. now owns 2,064,956 shares of the company's stock worth $3,800,000 after purchasing an additional 730,260 shares during the period. Samalin Investment Counsel LLC raised its holdings in shares of Nkarta by 81.4% in the 1st quarter. Samalin Investment Counsel LLC now owns 153,425 shares of the company's stock worth $282,000 after purchasing an additional 68,850 shares during the period. Finally, Monaco Asset Management SAM acquired a new position in shares of Nkarta in the 1st quarter valued at about $1,496,000. Institutional investors and hedge funds own 80.54% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近对 NKTX 的持仓进行了调整。Nuveen LLC 在第一季度购买了 Nkarta 的新头寸，价值 $258,000。Charles Schwab Investment Management Inc. 在第一季度增加了对 Nkarta 的持股，增幅为 18.0%。Charles Schwab Investment Management Inc. 目前拥有 147,551 股该公司的股票，价值 $271,000，此前在上个季度又增持了 22,538 股。Alyeska Investment Group L.P. 在第一季度将其在 Nkarta 的持股增加了 54.7%。Alyeska Investment Group L.P. 目前拥有 2,064,956 股该公司的股票，价值 $3,800,000，此前在此期间又购买了 730,260 股。Samalin Investment Counsel LLC 在第一季度将其在 Nkarta 的持股增加了 81.4%。Samalin Investment Counsel LLC 目前拥有 153,425 股该公司的股票，价值 $282,000，此前在此期间又购买了 68,850 股。最后，Monaco Asset Management SAM 在第一季度收购了 Nkarta 的新头寸，价值约 $1,496,000。机构投资者和对冲基金持有该公司 80.54% 的股票。</p>
</div><h2>Nkarta Company Profile</h2>
<div class="lb-trans"><h2>Nkarta 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.</p>
<div class="lb-trans"><p>Nkarta, Inc. 是一家临床阶段的生物制药公司，开发和商业化用于癌症和自身免疫性疾病治疗的自然杀伤细胞疗法。该公司的主要产品候选者是 NKX019，一种针对 CD19 抗原的嵌合抗原受体 - 自然杀伤细胞（CAR NK），目前正在进行针对复发/难治性（r/r）非霍奇金淋巴瘤的 1 期临床试验，以及用于狼疮性肾炎的治疗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Nkarta</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>3 Reasons On Holding’s Sell-Off Is Over and New Highs Are Coming</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>As Warren Buffett Nears His Exit, Berkshire's Amassed Record Cash</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>Rare Earth Stocks: The Truce That Isn't a Truce</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Nkarta</li>
<li>保护您的投资组合免受冠状病毒影响的 3 只股票</li>
<li>关于 Holding 的抛售结束和新高即将到来的 3 个理由</li>
<li>风险承受能力，适合所有人的一刀切并不适用</li>
<li>随着沃伦·巴菲特接近退休，伯克希尔的现金储备创下新纪录</li>
<li>现在购买 P&amp;G，在其创下新高之前</li>
<li>稀土股票：并非真正的休战</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=NKTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Nkarta Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Nkarta 吗？</h2>
</div><p>Before you consider Nkarta, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Nkarta 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Nkarta 并不在名单上。</p>
</div><p>While Nkarta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Nkarta 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Leerink Partners 上调了 Nkarta 的 2025 财年每股收益预期